Cargando…
Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683442/ https://www.ncbi.nlm.nih.gov/pubmed/19384026 http://dx.doi.org/10.4103/0301-4738.49406 |
| _version_ | 1782167115804966912 |
|---|---|
| author | Rishi, Pukhraj Rishi, Ekta Shroff, Daraius |
| author_facet | Rishi, Pukhraj Rishi, Ekta Shroff, Daraius |
| author_sort | Rishi, Pukhraj |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2683442 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | Medknow Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-26834422009-05-27 Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia Rishi, Pukhraj Rishi, Ekta Shroff, Daraius Indian J Ophthalmol Letters to the Editor Medknow Publications 2009 /pmc/articles/PMC2683442/ /pubmed/19384026 http://dx.doi.org/10.4103/0301-4738.49406 Text en © Indian Journal of Ophthalmology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Rishi, Pukhraj Rishi, Ekta Shroff, Daraius Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title_full | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title_fullStr | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title_full_unstemmed | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title_short | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| title_sort | combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683442/ https://www.ncbi.nlm.nih.gov/pubmed/19384026 http://dx.doi.org/10.4103/0301-4738.49406 |
| work_keys_str_mv | AT rishipukhraj combinedphotodynamictherapyandintravitrealbevacizumabasprimarytreatmentforsubretinalneovascularizationassociatedwithtype2idiopathicmaculartelangiectasia AT rishiekta combinedphotodynamictherapyandintravitrealbevacizumabasprimarytreatmentforsubretinalneovascularizationassociatedwithtype2idiopathicmaculartelangiectasia AT shroffdaraius combinedphotodynamictherapyandintravitrealbevacizumabasprimarytreatmentforsubretinalneovascularizationassociatedwithtype2idiopathicmaculartelangiectasia |